Dexmedetomidine and Postoperative Cognitive Dysfunction (POCD)

Continuous Dexmedetomidine Infusion Reduces Postoperative Cognitive Dysfunction and Postoperative Pain in Patients Undergoing Laparatomy

Status

Completed

Phases

Phase 4

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT06371638

Acronym

CODE-POCD

Enrollment

112

Registered

2024-04-17

Start date

2024-01-07

Completion date

2024-03-07

Last updated

2024-04-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Postoperative Cognitive Dysfunction, Postoperative Pain

Keywords

postoperative cognitive complications, dexmedetomidine, pain, hemodynamics

Brief summary

Postoperative cognitive dysfunction (POCD) affects all age groups and can lead to increased morbidity and more extended hospital stays. Dexmedetomidine reduces POCD by inhibiting the increase in proinflammatory cytokines IL-6 and TNF-α, and its anti-inflammatory activity contributes to its protective effect. Previous studies found that dexmedetomidine reduced POCD incidence in non-cardiac and cardiac surgery. Therefore, the goal of this study was to specifically investigate if using TCI dexmedetomidine to maintain anaesthesia in laparotomy surgeries reduces the incidence of POCD compared to inhalation anaesthesia by sevoflurane.

Interventions

DRUGDexmedetomidine

General anaesthesia for subjects in Group D was maintained by target-controlled infusion (TCI) dexmedetomidine (Dyck mode) with target plasma of 1 ng/ml

DRUGSevoflurane

General anaesthesia for subjects in Group I was maintained by inhalation anaesthesia using sevoflurane at 0.8% concentration.

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

PREVENTION

Masking

SINGLE (Subject)

Eligibility

Sex/Gender

ALL

Age

18 Years to 99 Years

Healthy volunteers

Inclusion criteria

* Aged \>= 18 years old * Scheduled for laparatomy surgery

Exclusion criteria

* history of allergies to anaesthetic drugs * impaired consciousness * neurocognitive disorder * psychiatric disorder * mental disorder * cerebrovascular disorders * sick sinus syndrome * hypoalbuminemia * massive bleeding * liver disease * kidney diseases.

Design outcomes

Primary

Measure	Time frame	Description
Postoperative cognitive dysfunction (POCD)	48 hours postoperative	Assessed by Mini-Mental State Examination (MMSE). Defined if there is a \>= 2 points decrease compared to baseline.

Secondary

Measure	Time frame	Description
Intraoperative hemodynamics: mean arterial pressure (MAP)	During the course of intraoperative period.	MAP as presented by intraoperative standard monitoring
Intraoperative hemodynamics: heart rate (HR)	During the course of intraoperative period.	HR as presented by intraoperative standard monitoring
Postoperative pain	1 hour postoperative	Assessed by visual analog scale (VAS), minimum value=0 (no pain), maximum=10 (worst pain)

Countries

Indonesia

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026